Zidovudine therapy of HIV-1 infection during pregnancy: Assessment of the effect on the newborns

Antonio Ferrazin, Andrea De Maria, Cristina Gotta, Giovanni Mazzarello, Andrea Canessa, Barbara Ciravegna, Carmela Cirillo, Francesco Melica, Alberto Terragna

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Zidovudine (ZDV) administration during pregnancy has been suggested for the prevention of mother-to-child HIV-1 transmission. Reliable levels of the drug have been observed in the fetus and in the newborn. Seven HIV-1-infected pregnant women who declined to have abortions and whose immunological status required antiretroviral treatment were administered oral ZDV 18 mg/kg in four daily doses, the initial dose being administered anytime from the 16th to the 30th week of gestation up until the time of delivery. Follow-up of the seven infants from birth with a mean duration of 22 months (range 16-32 months) revealed mild drug-related toxicity: anemia in two infants and macrocytosis in all seven, both conditions resolved by the second month of life. All infants remained HIV-1 seronegative, according to the 1987 CDC classification, and all stayed clinically well. Other virological parameters including virus culture, in vitro antibody production, and polymerase chain reaction, repeatedly performed in the infants, remained negative. Although none of the mothers transmitted HIV-1 infection to the offspring, the size of this study and the relatively low transmission rate (13%) in Europe do not permit us to draw a definite conclusion about treatment efficacy in preventing maternalfetal transmission. However, the drug caused only limited toxicity among the infants, and its administration to large numbers of mothers in treatment trials should be considered relatively safe for both mother and child.

Original languageEnglish
Pages (from-to)376-379
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume6
Issue number4
Publication statusPublished - 1993

Fingerprint

Zidovudine
HIV Infections
HIV-1
Newborn Infant
Pregnancy
Mothers
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Antibody Formation
Anemia
Pregnant Women
Fetus
Parturition
Viruses
Polymerase Chain Reaction

Keywords

  • HIV-1 prevention
  • Mother-to-child HIV-1 transmission
  • Pregnancy
  • Zidovudine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology and Allergy

Cite this

Ferrazin, A., Maria, A. D., Gotta, C., Mazzarello, G., Canessa, A., Ciravegna, B., ... Terragna, A. (1993). Zidovudine therapy of HIV-1 infection during pregnancy: Assessment of the effect on the newborns. Journal of Acquired Immune Deficiency Syndromes, 6(4), 376-379.

Zidovudine therapy of HIV-1 infection during pregnancy : Assessment of the effect on the newborns. / Ferrazin, Antonio; Maria, Andrea De; Gotta, Cristina; Mazzarello, Giovanni; Canessa, Andrea; Ciravegna, Barbara; Cirillo, Carmela; Melica, Francesco; Terragna, Alberto.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 6, No. 4, 1993, p. 376-379.

Research output: Contribution to journalArticle

Ferrazin, A, Maria, AD, Gotta, C, Mazzarello, G, Canessa, A, Ciravegna, B, Cirillo, C, Melica, F & Terragna, A 1993, 'Zidovudine therapy of HIV-1 infection during pregnancy: Assessment of the effect on the newborns', Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 4, pp. 376-379.
Ferrazin, Antonio ; Maria, Andrea De ; Gotta, Cristina ; Mazzarello, Giovanni ; Canessa, Andrea ; Ciravegna, Barbara ; Cirillo, Carmela ; Melica, Francesco ; Terragna, Alberto. / Zidovudine therapy of HIV-1 infection during pregnancy : Assessment of the effect on the newborns. In: Journal of Acquired Immune Deficiency Syndromes. 1993 ; Vol. 6, No. 4. pp. 376-379.
@article{a642fbdd8a1243e6a935935d9fcac19a,
title = "Zidovudine therapy of HIV-1 infection during pregnancy: Assessment of the effect on the newborns",
abstract = "Zidovudine (ZDV) administration during pregnancy has been suggested for the prevention of mother-to-child HIV-1 transmission. Reliable levels of the drug have been observed in the fetus and in the newborn. Seven HIV-1-infected pregnant women who declined to have abortions and whose immunological status required antiretroviral treatment were administered oral ZDV 18 mg/kg in four daily doses, the initial dose being administered anytime from the 16th to the 30th week of gestation up until the time of delivery. Follow-up of the seven infants from birth with a mean duration of 22 months (range 16-32 months) revealed mild drug-related toxicity: anemia in two infants and macrocytosis in all seven, both conditions resolved by the second month of life. All infants remained HIV-1 seronegative, according to the 1987 CDC classification, and all stayed clinically well. Other virological parameters including virus culture, in vitro antibody production, and polymerase chain reaction, repeatedly performed in the infants, remained negative. Although none of the mothers transmitted HIV-1 infection to the offspring, the size of this study and the relatively low transmission rate (13{\%}) in Europe do not permit us to draw a definite conclusion about treatment efficacy in preventing maternalfetal transmission. However, the drug caused only limited toxicity among the infants, and its administration to large numbers of mothers in treatment trials should be considered relatively safe for both mother and child.",
keywords = "HIV-1 prevention, Mother-to-child HIV-1 transmission, Pregnancy, Zidovudine",
author = "Antonio Ferrazin and Maria, {Andrea De} and Cristina Gotta and Giovanni Mazzarello and Andrea Canessa and Barbara Ciravegna and Carmela Cirillo and Francesco Melica and Alberto Terragna",
year = "1993",
language = "English",
volume = "6",
pages = "376--379",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Zidovudine therapy of HIV-1 infection during pregnancy

T2 - Assessment of the effect on the newborns

AU - Ferrazin, Antonio

AU - Maria, Andrea De

AU - Gotta, Cristina

AU - Mazzarello, Giovanni

AU - Canessa, Andrea

AU - Ciravegna, Barbara

AU - Cirillo, Carmela

AU - Melica, Francesco

AU - Terragna, Alberto

PY - 1993

Y1 - 1993

N2 - Zidovudine (ZDV) administration during pregnancy has been suggested for the prevention of mother-to-child HIV-1 transmission. Reliable levels of the drug have been observed in the fetus and in the newborn. Seven HIV-1-infected pregnant women who declined to have abortions and whose immunological status required antiretroviral treatment were administered oral ZDV 18 mg/kg in four daily doses, the initial dose being administered anytime from the 16th to the 30th week of gestation up until the time of delivery. Follow-up of the seven infants from birth with a mean duration of 22 months (range 16-32 months) revealed mild drug-related toxicity: anemia in two infants and macrocytosis in all seven, both conditions resolved by the second month of life. All infants remained HIV-1 seronegative, according to the 1987 CDC classification, and all stayed clinically well. Other virological parameters including virus culture, in vitro antibody production, and polymerase chain reaction, repeatedly performed in the infants, remained negative. Although none of the mothers transmitted HIV-1 infection to the offspring, the size of this study and the relatively low transmission rate (13%) in Europe do not permit us to draw a definite conclusion about treatment efficacy in preventing maternalfetal transmission. However, the drug caused only limited toxicity among the infants, and its administration to large numbers of mothers in treatment trials should be considered relatively safe for both mother and child.

AB - Zidovudine (ZDV) administration during pregnancy has been suggested for the prevention of mother-to-child HIV-1 transmission. Reliable levels of the drug have been observed in the fetus and in the newborn. Seven HIV-1-infected pregnant women who declined to have abortions and whose immunological status required antiretroviral treatment were administered oral ZDV 18 mg/kg in four daily doses, the initial dose being administered anytime from the 16th to the 30th week of gestation up until the time of delivery. Follow-up of the seven infants from birth with a mean duration of 22 months (range 16-32 months) revealed mild drug-related toxicity: anemia in two infants and macrocytosis in all seven, both conditions resolved by the second month of life. All infants remained HIV-1 seronegative, according to the 1987 CDC classification, and all stayed clinically well. Other virological parameters including virus culture, in vitro antibody production, and polymerase chain reaction, repeatedly performed in the infants, remained negative. Although none of the mothers transmitted HIV-1 infection to the offspring, the size of this study and the relatively low transmission rate (13%) in Europe do not permit us to draw a definite conclusion about treatment efficacy in preventing maternalfetal transmission. However, the drug caused only limited toxicity among the infants, and its administration to large numbers of mothers in treatment trials should be considered relatively safe for both mother and child.

KW - HIV-1 prevention

KW - Mother-to-child HIV-1 transmission

KW - Pregnancy

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0027480633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027480633&partnerID=8YFLogxK

M3 - Article

C2 - 8455142

AN - SCOPUS:0027480633

VL - 6

SP - 376

EP - 379

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -